• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Adjuvant therapy for intrahepatic carcinoma after surgical resection: chemotherapy and future perspectives.肝内癌手术切除后的辅助治疗：化疗及未来展望。
Hepatobiliary Surg Nutr. 2021 Dec;10(6):878-880. doi: 10.21037/hbsn-21-368.
2
Adjuvant hepatic arterial infusion chemotherapy with 5-Fluorouracil and interferon after curative resection of hepatocellular carcinoma: a preliminary report.根治性切除术后辅助肝动脉灌注化疗联合氟尿嘧啶和干扰素治疗肝细胞癌：初步报告。
Anticancer Res. 2013 Dec;33(12):5585-90.
3
Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study.肝细胞癌：手术切除与手术切除联合术前及术后局部区域免疫治疗-化疗。一项前瞻性随机研究。
Anticancer Res. 1995 Mar-Apr;15(2):543-50.
4
A novel intrahepatic arterial chemotherapy after radical resection for advanced hepatocellular carcinoma.晚期肝细胞癌根治性切除术后的一种新型肝内动脉化疗。
Hepatogastroenterology. 2005 May-Jun;52(63):862-5.
5
The role of adjuvant therapy after R0 resection for patients with intrahepatic and perihilar cholangiocarcinomas.R0切除术后辅助治疗在肝内胆管癌和肝门周围胆管癌患者中的作用。
Cancer Chemother Pharmacol. 2017 Jan;79(1):99-106. doi: 10.1007/s00280-016-3206-4. Epub 2016 Dec 7.
6
[Cholangiocellular cancer: the state of the problem and ways to improve the results of surgical treatment].[胆管细胞癌：问题现状及改善手术治疗效果的方法]
Khirurgiia (Mosk). 2018(12):30-37. doi: 10.17116/hirurgia201812130.
7
Prognosis of the intrahepatic cholangiocarcinoma after resection: hepatitis B virus infection and adjuvant chemotherapy are favorable prognosis factors.肝内胆管细胞癌切除术后的预后：乙型肝炎病毒感染和辅助化疗是有利的预后因素。
Cancer Cell Int. 2013 Oct 18;13(1):99. doi: 10.1186/1475-2867-13-99.
8
The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts.手术及辅助治疗在胆囊和肝内胆管淋巴结阳性癌症中的作用。
Cancer. 2018 Jan 1;124(1):74-83. doi: 10.1002/cncr.30968. Epub 2017 Aug 25.
9
Staging, prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma after curative resection.肝内胆管癌根治性切除术后的分期、预后因素及辅助治疗
Liver Int. 2014 Jul;34(6):953-60. doi: 10.1111/liv.12364. Epub 2013 Nov 20.
10
Postoperative adjuvant locoregional chemotherapy in patients with hepatocellular carcinoma.肝细胞癌患者的术后辅助局部区域化疗
Hepatogastroenterology. 1996 Nov-Dec;43(12):1415-20.

引用本文的文献

1
Liver transplantation for cholangiocarcinoma: exploring a new land.胆管癌的肝移植：探索新领域。
J Gastrointest Oncol. 2022 Oct;13(5):2696-2698. doi: 10.21037/jgo-22-596.

本文引用的文献

1
Influence of postoperative adjuvant transarterial chemoembolization on the prognosis of early-stage intrahepatic cholangiocarcinoma: a single center study.术后辅助经动脉化疗栓塞对早期肝内胆管癌预后的影响：一项单中心研究
Ann Palliat Med. 2021 Apr;10(4):3673-3683. doi: 10.21037/apm-20-1337. Epub 2021 Feb 23.
2
Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: approaching clinical practice consensus?肝内胆管癌的辅助化疗：达成临床实践共识？
Hepatobiliary Surg Nutr. 2020 Oct;9(5):577-586. doi: 10.21037/hbsn.2019.06.12.
3
Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers.基于下一代测序的胆管癌分子靶向治疗和免疫治疗。
Cancer Immunol Immunother. 2021 Apr;70(4):1001-1014. doi: 10.1007/s00262-020-02745-y. Epub 2020 Oct 23.
4
Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives.胆道癌循环肿瘤 DNA：当前证据和未来展望。
Cancer Genomics Proteomics. 2020 Sep-Oct;17(5):441-452. doi: 10.21873/cgp.20203.
5
Systemic treatment of advanced or recurrent biliary tract cancer.晚期或复发性胆道癌的系统治疗。
Biosci Trends. 2020 Nov 4;14(5):328-341. doi: 10.5582/bst.2020.03240. Epub 2020 Aug 24.
6
Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.IDH1/2 突变和其他常见突变在大导管型和小导管型肝内胆管细胞癌中的不同临床和预后意义。
BMC Cancer. 2020 Apr 15;20(1):318. doi: 10.1186/s12885-020-06804-6.
7
Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.分子靶向治疗：在胆管癌中准备“黄金时间”。
J Hepatol. 2020 Jul;73(1):170-185. doi: 10.1016/j.jhep.2020.03.007. Epub 2020 Mar 12.
8
Effectiveness of Olaparib Treatment in a Patient with Gallbladder Cancer with an ATM-Inactivating Mutation.奥拉帕利治疗携带 ATM 失活突变的胆囊癌患者的疗效。
Oncologist. 2020 May;25(5):375-379. doi: 10.1634/theoncologist.2019-0498. Epub 2020 Feb 11.
9
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.卡培他滨对比观察用于可切除胆管癌（BILCAP）：一项随机、对照、多中心、3 期研究。
Lancet Oncol. 2019 May;20(5):663-673. doi: 10.1016/S1470-2045(18)30915-X. Epub 2019 Mar 25.
10
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.吉西他滨和奥沙利铂化疗或监测在切除的胆管癌 (PRODIGE 12-ACCORD 18-UNICANCER GI)：一项随机 III 期研究。
J Clin Oncol. 2019 Mar 10;37(8):658-667. doi: 10.1200/JCO.18.00050. Epub 2019 Feb 1.

Adjuvant therapy for intrahepatic carcinoma after surgical resection: chemotherapy and future perspectives.

作者信息

Zhang Wei, Song Tianqiang

机构信息

Department of Hepatobiliary Cancer, Research Center for Prevention and Treatment of Liver Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.

出版信息

Hepatobiliary Surg Nutr. 2021 Dec;10(6):878-880. doi: 10.21037/hbsn-21-368.

DOI:10.21037/hbsn-21-368
PMID:35004960
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8683914/
Abstract
摘要